Study sites and patient selection
SAKK, TNBC
This prospective, proof-of concept, open-label multicenter phase II trial (SAKK 24/14; NCT02833766) was designed with a single-stage single-arm layout. We accrued patients at 12 participating sites across Switzerland.Patients met inclusion criteria if they presented with metastatic or locally advanced, inoperable TNBC with an EGFR expression of at least (1 +) on immunohistochemistry according to the EGFR pharmDx™ Interpretation Guidelines